Lead optimization attrition analysis (LOAA): a novel and general methodology for medicinal chemistry

Drug Discovery Today

Volumn 20, Issue 8, 2015, Pages 978-987

  Munson, Mark ^a   Lieberman, Harvey ^a   Tserlin, Elina ^b   Rocnik, Jennifer ^c   Ge, Jie ^c   Fitzgerald, Maria ^d   Patel, Vinod ^a   Garcia Echeverria, Carlos ^e  

^a Lead Generation and Candidate Realization   (United States)

^b Sanofi   (United States)

^c Oncology Department   (United States)

^d DMPK   (United States)

^e SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; ANALYTICAL PARAMETERS; ARTICLE; CASE STUDY; COMPUTER GRAPHICS; CONSENSUS; DATA ANALYSIS SOFTWARE; DECISION MAKING; DRUG DESIGN; DRUG INDUSTRY; HUMAN; LEAD OPTIMIZATION ATTRITION ANALYSIS; MEDICINAL CHEMISTRY; MOLECULE; NONHUMAN; ONCOLOGY; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PROCESS OPTIMIZATION; QUALITY CONTROL; STRATEGIC PLANNING; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY; ALGORITHM; ANIMAL; BIOASSAY; BIOLOGICAL MODEL; CHEMISTRY; DECISION SUPPORT SYSTEM; DRUG DEVELOPMENT; PROCEDURES; SOFTWARE; STATISTICAL MODEL;

ANTINEOPLASTIC AGENT;

ALGORITHMS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL ASSAY; CHEMISTRY, PHARMACEUTICAL; DECISION SUPPORT TECHNIQUES; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; SOFTWARE;

EID: 84940614654     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.03.010     Document Type: Review

References (37)

1. J. Karamehic, and et al. Financial aspects and the future of the pharmaceutical industry in the United States of America Mater. Sociomed. 25 2013 286 290
2. A. Daemmrich, and A. Mohanty Healthcare reform in the United States and China: pharmaceutical market implications J. Pharm. Policy Pract. 7 2014 9
3. J. Hamdam, and et al. Safety pharmacology: current and emerging concepts Toxicol. Appl. Pharmacol. 273 2013 229 241
4. M. Abou-Gharbia, and W.E. Childers Discovery of innovative therapeutics: today's realities and tomorrow's vision. 2. Pharma's challenges and their commitment to innovation J. Med. Chem. 57 2014 5525 5553
5. P. Workman, and B. Al-Lazikani Drugging cancer genomes Nat. Rev. Drug Discov. 12 2013 889 890
6. S. Guo, and et al. Advances in the proteomic discovery of novel therapeutic targets in cancer Drug Des. Devel. Ther. 7 2013 1259 1271
7. J. Besnard, and et al. Automated design of ligands to polypharmacological profiles Nature 492 2012 215 220
8. G. Sliwoski, and et al. Computational methods in drug discovery Pharmacol. Rev. 66 2014 334 395
9. A. Chighine, and et al. Tools for efficient high-throughput synthesis Drug Discov. Today 12 2007 459 464
10. G.W. Festel The nature of outsourced preclinical research: the example of chemical synthesis Expert Opin. Drug Discov. 8 2013 1049 1055
11. M. Liu, and et al. Role of text mining in early identification of potential drug safety issues Methods Mol. Biol. 1159 2014 227 251
12. M.J. Wawer, and et al. Automated structure-activity relationship mining: connecting chemical structure to biological profiles J. Biomol. Screen. 19 2014 738 748
13. M.P. Gleeson, and et al. In-silico ADME models: a general assessment of their utility in drug discovery applications Curr. Top. Med. Chem. 11 2011 358 381
14. D.F. Ortwine, and I. Aliagas Physicochemical and DMPK in silico models: facilitating their use by medicinal chemists Mol. Pharmaceutics 10 2013 1153 1161
15. M. Segall Advances in multiparameter optimization methods for de novo drug design Expert Opin. Drug Discov. 9 2014 803 817
16. M.D. Segall, and C. Barber Addressing toxicity risk when designing and selecting compounds in early drug discovery Drug Discov. Today 19 2014 688 693
17. I. Yusof, and et al. Finding the rules for successful drug optimisation Drug Discov. Today 19 2014 680 687
18. S.M. Paul, and et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
19. T.J. Ritchie, and S.J.F. Macdonald How drug-like are 'ugly' drugs: do drug-likeness metrics predict ADME behaviour in humans? Drug Discov. Today 19 2014 489 495
20. C. Abad-Zapatero, and et al. Alternative variables in drug discovery: promises and challenges Future Med. Chem. 6 2014 577 593
21. C.A. Lipinski, and et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 23 1997 3 25
22. W.P. Walters Going further than Lipinski's rule in drug design Expert Opin. Drug Discov. 7 2012 99 107
23. G.M. Keserue, and G.M. Makara The influence of lead discovery strategies on the properties of drug candidates Nat. Rev. Drug Discov. 8 2009 203 212
24. D.A. Price, and et al. Physicochemical drug properties associated with in vivo toxicological outcomes: a review Expert Opin. Drug Metab. Toxicol. 5 2009 921 931
25. S.S. Jambhekar, and P.J. Breen Drug dissolution: significance of physicochemical properties and physiological conditions Drug Discov. Today 18 2013 1173 1184
26. I. Yusof, and M.D. Segall Considering the impact drug-like properties have on the chance of success Drug Discov. Today 18 2013 659 666
27. A.L. Hopkins, and et al. The role of ligand efficiency metrics in drug discovery Nat. Rev. Drug Discov. 13 2014 105 121
28. M.D. Shultz Improving the plausibility of success with inefficient metrics ACS Med. Chem. Lett. 5 2014 2 5
29. P.W. Kenny, and et al. Ligand efficiency metrics considered harmful J. Comput. Aided Mol. Des. 28 2014 699 710
30. C.A. Lipinski Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 44 2000 235 249
31. J.W. Scannell, and et al. Diagnosing the decline in pharmaceutical R&D efficiency Nat. Rev. Drug Discov. 11 2012 191 200
32. K. Arnold, and et al. Value drivers in licensing deals Nat. Biotechnol. 20 2002 1085 1089
33. J. Arrowsmith, and P. Miller Trial Watch Phase II and Phase III attrition rates 2011-2012 Nat. Rev. Drug Discov. 12 2013 569
34. F. Pammolli, and et al. The productivity crisis in pharmaceutical R&D Nat. Rev. Drug Discov. 10 2011 428 438
35. M. Herper The cost of creating a new drug now $5 billion, pushing big pharma to change Forbes Magazine: Pharma and Healthcare 8 November 2013
36. M. Hay, and et al. Clinical development success rates for investigational drugs Nat. Biotechnol. 32 2014 40 51
37. N.N. Taleb Antifragile: Things that Gain from Disorder 2012 Random House